Sartorius Stedim Biotech Valuation

Is DIM N undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DIM N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DIM N (MX$4417.56) is trading above our estimate of fair value (MX$1961.17)

Significantly Below Fair Value: DIM N is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DIM N?

Key metric: As DIM N is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DIM N. This is calculated by dividing DIM N's market cap by their current earnings.
What is DIM N's PE Ratio?
PE Ratio	79.1x
Earnings	€309.70m
Market Cap	€24.51b

DIM N key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	10.1x
Enterprise Value/EBITDA	42.7x
PEG Ratio	3.8x

Price to Earnings Ratio vs Peers

How does DIM N's PE Ratio compare to its peers?

The above table shows the PE ratio for DIM N vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	32x
MTD Mettler-Toledo International	31.2x	7.8%	US$24.9b
WST West Pharmaceutical Services	44.5x	12.7%	US$22.8b
603259 WuXi AppTec	18.5x	15.4%	CN¥147.1b
WAT Waters	33.9x	8.6%	US$21.3b
DIM N Sartorius Stedim Biotech	79.1x	21.0%	Mex$24.5b

Price-To-Earnings vs Peers: DIM N is expensive based on its Price-To-Earnings Ratio (79.1x) compared to the peer average (57.4x).

Price to Earnings Ratio vs Industry

How does DIM N's PE Ratio compare vs other companies in the Global Life Sciences Industry?

3 Companies	Price / Earnings	Estimated Growth	Market Cap

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: DIM N is expensive based on its Price-To-Earnings Ratio (79.1x) compared to the Global Life Sciences industry average (33.9x).

Price to Earnings Ratio vs Fair Ratio

What is DIM N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DIM N PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	79.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate DIM N's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

ROVI N

€1,416.38

54.7%

ICON

US$15.7b

A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.

ICLR N

US$4,286.08

3.3%

-7.7%

CSPC Pharmaceutical Group

HK$69.4b

An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.

1093 N

HK$15.69

-27.0%